News
ATYR
0.5129
-3.34%
-0.0177
aTyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker
Dow Jones · 1d ago
aTyr Pharma Raised to Buy From Hold by Freedom Broker
Dow Jones · 1d ago
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
TipRanks · 1d ago
RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)
TipRanks · 2d ago
Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)
TipRanks · 3d ago
Weekly Report: what happened at ATYR last week (0511-0515)?
Weekly Report · 3d ago
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
TipRanks · 5d ago
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
TipRanks · 6d ago
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
TipRanks · 6d ago
aTyr Pharma GAAP EPS of -$0.11 beats by $0.04
Seeking Alpha · 6d ago
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal
NASDAQ · 6d ago
aTyr Pharma plans Phase 3 efzofitimod trial in restrictive pulmonary sarcoidosis
PUBT · 6d ago
ATYR PHARMA ANNOUNCES FIRST QUARTER 2026 RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 6d ago
Press Release: aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Dow Jones · 6d ago
Press Release: aTyr Pharma Announces First -2-
Dow Jones · 6d ago
*ATyr Pharma 1Q Loss/Shr 11c >ATYR
Dow Jones · 6d ago
Atyr Pharma: Q1 Earnings Snapshot
Barchart · 6d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 05/14 17:06
aTyr Pharma plans Phase 3 pulmonary sarcoidosis trial of efzofitimod with FVC endpoint
PUBT · 05/13 20:07
aTyr Pharma to present at Jefferies Global Healthcare Conference fireside chat
PUBT · 05/13 20:02
More
Webull provides a variety of real-time ATYR stock news. You can receive the latest news about Atyr Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).